Athanasios Tsianakas
Von Esmarch Str. 58
Muenster, NW 48149, Germany
Muenster, NW 48149, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications
Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study.
Journal: Dermatology and therapy
Published: May 07, 2026
Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 08, 2026
Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.
Journal: Lancet (London, England)
Published: March 06, 2026
Tildrakizumab Real-World Experience (T-REX) in Plaque Psoriasis: Meta-Analysis of Four Non-interventional Studies.
Journal: Dermatology and therapy
Published: January 27, 2026
Impact of Oral DFD-29, a Low-Dose Formulation of Minocycline, on Quality of Life in Patients with Rosacea: Results of Two Phase 3 Randomized Controlled Trials.
Journal: The Journal of clinical and aesthetic dermatology
Published: December 19, 2025
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: October 10, 2025
Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.
Journal: Acta dermato-venereologica
Published: October 08, 2025
Disclosing the Overall and Sex-Related Disease Burden and Treatment Needs of Patients With Anogenital Psoriasis: Results From the Case-Control PsoGen Study.
Journal: Dermatology research and practice
Published: July 31, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials.
Journal: Lancet (London, England)
Published: July 08, 2025
Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study.
Journal: Journal of the American Academy of Dermatology
Published: April 22, 2025
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial.
Journal: Journal of the American Academy of Dermatology
Published: April 10, 2025
Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicentre phase IIIb/IV study (Flex Up).
Journal: The British journal of dermatology
Published: April 01, 2025
Last Updated: 09/26/2026